Navigation Links
WallSt.net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies
Date:12/17/2007

NEW YORK, Dec. 17 /PRNewswire/ -- David B. Phillips, CEO of ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) (http://www.rebuildermedical.com) will be featured in an exclusive interview with http://www.wallst.net scheduled for December 18th. The interview will be posted on http://www.wallst.net by 8 p.m. EST on December 18th.

The interview will cover topics including ReBuilder Medical Technologies, Inc.'s market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol (RBRM) under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window.

About ReBuilder Medical Technologies:

RBRM is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company's flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery-powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.

ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.

More information on ReBuilder Medical Technologies, Inc. and its products can be found at: http://www.rebuildermedical.com and http://www.molluscum.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Website is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, Financial Filings Corp., a provider of compliance solutions to publicly traded companies, and WallStRadio, a business and finance podcast Website. Financial Filings Corp. is expecting to receive two hundred eighty dollars from ReBuilder Medical Technologies, Inc. for the dissemination of this press release. For a complete list of our advertisers and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

Contact: WallSt.net

800-4-WALL-ST


'/>"/>
SOURCE Financial Filings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of Osteologix
2. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
3. WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals
4. WallSt.net Announces Upcoming Interview With CEO of Biomoda
5. Synvista Therapeutics to be Featured on Wallst.net
6. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
Breaking Biology News(10 mins):